World Health Organization Sounds Alert Over Severe Scarcity of Weight-Loss Injections

Less than 10% of patients eligible to benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it releases its first recommendations on the therapies.

With in excess of 1,000,000,000 people worldwide currently obese, it is calling for broader and more equitable access to these injectable treatments.

Based on estimates, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.

"Our latest guidance recognises that excess weight is a long-term condition that can be addressed with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are key obstacles to widespread access to the treatments that can help people shift significant body mass, notes the agency.

Skinny Jab Supply Crisis

Despite the present most optimistic case, the manufacturing of these medications might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.

The advice calls on countries and companies to increase access, via strategies such as patent sharing.

A patent on the active ingredient – the primary ingredient of a leading brand – is due to expire in multiple nations in 2026.

How Weight-Loss Injections Work

The injections mimick a body's own hormone to slow digestion, suppress the appetite and increase satiety so people eat less.

Individuals commonly start to lose weight within a few weeks of commencing the regular doses.

Studies suggests patients may regain a significant portion within a year of halting the treatment, because their usual hunger resume.

To be overweight or obese elevates your chance for developing health problems, such as diabetes, heart disease, brain attack, and some malignancies.

Excess weight affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.